




## Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-025-03715-6>,  
published online 27 May 2025.

<https://doi.org/10.1038/s41591-025-03904-3>

Published online: 1 August 2025

Nicola Miglino, Nora C. Toussaint , Alexander Ring, Ximena Bonilla , Marina Tusup, Benedict Gosztanyi, Tarun Mehra , Gabriele Gut, Francis Jacob , Stephane Chevrier, Kjong-Van Lehmann, Ruben Casanova, Andrea Jacobs, Sujana Sivapatham, Laura Boos, Parisa Rahimzadeh , Manuel Schuerch, Bettina Sobottka, Natalia Chicherova , Shuqing Yu, Rebekka Wegmann , Julien Mena , Emanuela S. Milani, Sandra Goetze , Cinzia Esposito, Jacobo Sarabia del Castillo, Anja L. Frei, Marta Nowak, Anja Irmisch, Jack Kuipers, Monica-Andreea Baciú-Drăgan, Pedro F. Ferreira, Franziska Singer , Anne Bertolini , Michael Prummer , Ulrike Lischetti, Tumor Profiler Consortium\*, Rudolf Aebersold , Marina Bacac, Gerd Maass, Holger Moch , Michael Weller , Alexandre P. A. Theocharides, Markus G. Manz , Niko Beerenwinkel , Christian Beisel , Lucas Pelkmans, Berend Snijder, Bernd Wollscheid, Viola Heinzelmann, Bernd Bodenmiller , Mitchell P. Levesque , Viktor H. Koelzer , Gunnar Rättsch, Reinhard Dummer  & Andreas Wicki 

In the version of the article initially published, the far-right column of the lower panel in Fig. 2c was missing and has now been added, as seen in Fig. 1, below. Additionally, the sentence “L.P. is a founder and shareholder of Apricot Therapeutics - a precision oncology spin-off from the University of Zurich - based on 4i drug response profiling” was missing from the Competing interests statement and has now been added. These corrections have been made to the HTML and PDF versions of the article.

\*A list of authors and their affiliations appears at the end of the paper.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025




Fig. 1 | Original and corrected Fig. 2c.

## Publisher Correction: AI-enabled drug discovery reaches clinical milestone

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-025-03832-2>,  
published online 1 July 2025.

<https://doi.org/10.1038/s41591-025-03897-z>

Published online: 21 July 2025

Marinka Zitnik

In the version of the article initially published, in the third paragraph, the text “–0.3 ml in the placebo arm” should have read “–20.3 ml in the placebo arm” and has now been corrected in the HTML and PDF versions of the article.

© Springer Nature America, Inc. 2025

## Publisher Correction: Integrating liver endpoints in clinical trials of cardiovascular and kidney disease

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-024-03223-z>,  
published online 3 September 2024.

<https://doi.org/10.1038/s41591-025-03818-0>

Published online: 12 June 2025

Faiez Zannad , Arun J. Sanyal , Javed Butler, Veronica Miller &  
Stephen A. Harrison

In the version of the article initially published, an incorrect version of Fig. 1 was included. Figure 1 has now been updated in the HTML and PDF versions of the article.

© Springer Nature America, Inc. 2025